Alnylam Pharmaceuticals, Inc. (ALNY) Expected to Announce Earnings of -$1.80 Per Share

Equities research analysts expect that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will report earnings per share of ($1.80) for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Alnylam Pharmaceuticals’ earnings. The highest EPS estimate is ($1.57) and the lowest is ($1.95). Alnylam Pharmaceuticals reported earnings of ($1.06) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 69.8%. The business is scheduled to report its next quarterly earnings report on Tuesday, November 6th.

According to Zacks, analysts expect that Alnylam Pharmaceuticals will report full year earnings of ($6.66) per share for the current year, with EPS estimates ranging from ($6.96) to ($6.11). For the next financial year, analysts forecast that the company will report earnings of ($7.41) per share, with EPS estimates ranging from ($8.74) to ($6.37). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.74) by $0.11. The business had revenue of $29.91 million for the quarter, compared to the consensus estimate of $16.96 million. Alnylam Pharmaceuticals had a negative return on equity of 38.09% and a negative net margin of 533.52%. The firm’s quarterly revenue was up 87.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.07) earnings per share.

Several equities research analysts have weighed in on ALNY shares. Needham & Company LLC restated a “buy” rating and set a $152.00 target price on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 13th. ValuEngine cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 21st. Cowen restated a “buy” rating and set a $157.00 target price on shares of Alnylam Pharmaceuticals in a research note on Thursday, August 2nd. BidaskClub cut Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 2nd. Finally, BMO Capital Markets cut their target price on Alnylam Pharmaceuticals from $127.00 to $125.00 and set an “outperform” rating for the company in a research note on Monday, August 13th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and sixteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $144.17.

NASDAQ:ALNY traded down $1.65 during trading hours on Wednesday, reaching $81.26. 451,200 shares of the company were exchanged, compared to its average volume of 904,516. The company has a market capitalization of $8.81 billion, a P/E ratio of -14.99 and a beta of 2.56. Alnylam Pharmaceuticals has a 1-year low of $78.85 and a 1-year high of $153.99. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.22 and a quick ratio of 13.22.

In other news, COO Yvonne Greenstreet sold 2,500 shares of the stock in a transaction on Thursday, August 30th. The stock was sold at an average price of $120.00, for a total value of $300,000.00. Following the completion of the transaction, the chief operating officer now directly owns 1,916 shares in the company, valued at approximately $229,920. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John Maraganore sold 50,000 shares of the stock in a transaction on Wednesday, July 25th. The shares were sold at an average price of $105.39, for a total value of $5,269,500.00. Following the completion of the transaction, the chief executive officer now owns 201,297 shares of the company’s stock, valued at $21,214,690.83. The disclosure for this sale can be found here. 3.70% of the stock is currently owned by corporate insiders.

A number of large investors have recently made changes to their positions in ALNY. Nelson Van Denburg & Campbell Wealth Management Group LLC bought a new position in Alnylam Pharmaceuticals during the 2nd quarter worth $137,000. Mutual of America Capital Management LLC raised its position in Alnylam Pharmaceuticals by 98.5% during the 2nd quarter. Mutual of America Capital Management LLC now owns 1,935 shares of the biopharmaceutical company’s stock worth $191,000 after purchasing an additional 960 shares during the last quarter. IPG Investment Advisors LLC bought a new position in Alnylam Pharmaceuticals during the 2nd quarter worth $217,000. First Republic Investment Management Inc. bought a new position in Alnylam Pharmaceuticals during the 2nd quarter worth $230,000. Finally, Riverhead Capital Management LLC raised its position in Alnylam Pharmaceuticals by 195.6% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,365 shares of the biopharmaceutical company’s stock worth $233,000 after purchasing an additional 1,565 shares during the last quarter. 93.41% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.

Read More: Penny Stocks, Risk and Reward Factors

Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply